Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts both pediatrics and adults. Despite the availability and proven efficacy of systemic medications, there remains a critical issue of non-adherence among patients. This study aimed to assess adherence to systemic therapy among Saudi adult patients with AD.
Methods: The study employed a cross-sectional study with an online questionnaire that was distributed among a convenience sample of 1,154 adult patients with AD in Saudi Arabia. In addition to descriptive statistical analysis, Pearson's correlation and chi-squared tests were used to determine the correlations between adherence to systemic therapy for AD and its predictable factors.
Results: AD was diagnosed over five years in 61.3% of the participants. The vast majority of those diagnosed with AD (73%) were prescribed systemic medications, with a moderate level of adherence to this therapy. While adherence to systemic therapy significantly correlated with improved quality of life, factors including forgetfulness, side effect concerns, patient's belief in medication importance, disease severity, and medication complexity impacted adherence to this mode of therapy. Factors including patient's belief in medication importance, disease severity, and medication complexity impacted adherence.
Conclusion: The findings of this study highlight the need for multifaceted interventions to improve adherence to systemic therapy for AD. Addressing patient concerns about the use of systemic therapy for AD and reinforcing the importance of medication use for long-term disease management and quality-of-life improvement is recommended to explore the barriers to adherence and enhance compliance to systemic therapy in this population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610529 | PMC |
http://dx.doi.org/10.7759/cureus.72866 | DOI Listing |
Ophthalmol Ther
January 2025
Corneoplastic Unit and Eye Bank, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.
Introduction: This study compared the clinical outcomes of allogenic cultured limbal epithelial transplantation (ACLET) and cultivated oral mucosal epithelial transplantation (COMET) in the management of limbal stem cell deficiency (LSCD).
Methods: Forty-one COMET procedures in 40 eyes and 69 ACLET procedures in 54 eyes were performed in the Corneoplastic Unit of Queen Victoria Hospital, East Grinstead. Data were examined for demographics, indications, ocular surface stability, absence of epithelial defect, ocular surface inflammation, visual outcomes, and intra- and postoperative complications.
Ophthalmol Ther
January 2025
Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Congenital Aniridia Research, Saarland University, Homburg, Saar, Germany.
Introduction: Congenital aniridia is increasingly recognized as part of a complex syndrome with numerous ocular developmental anomalies and non-ocular systemic manifestations. This requires comprehensive care and treatment of affected patients. Our purpose was to analyze systemic diseases in patients with congenital aniridia within the Homburg Aniridia Registry.
View Article and Find Full Text PDFRadiat Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases.
Methods: This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible.
J Cardiothorac Surg
January 2025
Department of Radiology, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130000, Jilin, China.
Background: Anomalous systemic artery to the left lower lobe (ASALLL) is a rare congenital anomaly. The primary symptoms include hemoptysis and lung infection, though some patients may remain asymptomatic. Currently, there is no consensus on the indications for treatment or the optimal choice of therapy for this condition.
View Article and Find Full Text PDFJ Transl Med
January 2025
Evvivax Biotech, Via Castel Romano 100, 00128, Rome, Italy.
In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing process to produce clinical-grade CAR-T cells is complex, time-consuming, and highly expensive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!